The document summarizes a study evaluating the MO.MA device for proximal cerebral protection during carotid artery stenting. Some key points: - The ARMOUR study was a prospective, multicenter trial of 225 high surgical risk patients undergoing carotid stenting with the MO.MA device. - The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE) within 30 days, which occurred in 2.7% of patients. - The MO.MA device demonstrated high rates of device success (98.2%), technical success (94.6%), and procedural success (93.2%). - 30-day results compare favorably to historical CAS studies and showed no increased risk for symptomatic